Dr Reddy's launches new drug in urology segment

Dr Reddy's Laboratories Ltd has announced the launch of alfuzosin hydrochloride - indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH).

In a press release on Monday, the company said alfuzosin hydrochloride is being introduced under the brand name `Alfoo' and is available in extended release tablets of 10 mg dosage.

According to the company, alfuzosin scores over other alpha-blockers by way of providing rapid relief from signs and symptoms of BPH to offer a better quality of life.

The company said Alfoo would further help it consolidate its position in the urology segment, where it already has strong brands present.

The product is being made available in over 5,700 retail counters across the nation and is being marketed by a strong field force of over 100 scientific business officers, the company said.

Common in aging men

BPH is the most common non neo-plastic disorder of aging in men. The prevalence of BPH increases from 8% in men between 31 and 40 years of age to 50% in men between 51 and 60 years of age.

The company currently has over 10 products in the urology segment of which Finast (Finasteride), Dutas (Dutasteride) and Dynapres (Tamsulosin) are leading brands.

The market size for the product (alfuzosin hydrochloride) as per April data is valued at Rs 27 crore. The urology segment is estimated at over Rs 65 crore, the company said.

Taken from Business Line

thehindubusinessline.in